Movement Alert｜DUALITYBIO-B Rises 5.09% in Regular Trading, Biotech Sector Strength Drives Rebound Continuation

Market Focus08-07

On August 7, DUALITYBIO-B rose 5.09% in regular trading, trading at 191.6 HKD/share, with turnover of approximately HKD 149 million. The stock had previously plunged 13.7% on July 30 due to GSK competitive pressure and has been gradually stabilizing in recent sessions.

On the news front, the Hong Kong-listed biotech sector rallied broadly, with Remegen up 8.99%, Transthera-B up 7.11%, BeOne Medicines up 4.86%, Akeso up 3.96%, and Innovent Bio up 2.86%, reflecting a significant recovery in sector sentiment that lifted DUALITYBIO-B in tandem. Additionally, the company's core pipeline B7-H3 ADC (Elfe-D) recently received NMPA Breakthrough Therapy Designation, while its A-share IPO application has been accepted by the Shanghai Stock Exchange and entered the inquiry stage. Multiple brokerages have issued Buy ratings, with Dongwu Securities initiating coverage and projecting revenue of RMB 2.05 billion to RMB 2.60 billion for the period ahead. These fundamental catalysts continue to accumulate, supporting ongoing valuation recovery.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179387639?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 14:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179387639","market":"us","top_or_hot":-1,"title":"Movement Alert｜DUALITYBIO-B Rises 5.09% in Regular Trading, Biotech Sector Strength Drives Rebound Continuation","media":"Market Focus","content":"<p><p>On August 7, DUALITYBIO-B rose 5.09% in regular trading, trading at 191.6 HKD/share, with turnover of approximately HKD 149 million. The stock had previously plunged 13.7% on July 30 due to GSK competitive pressure and has been gradually stabilizing in recent sessions.</p><p>On the news front, the Hong Kong-listed biotech sector rallied broadly, with Remegen up 8.99%, Transthera-B up 7.11%, BeOne Medicines up 4.86%, Akeso up 3.96%, and Innovent Bio up 2.86%, reflecting a significant recovery in sector sentiment that lifted DUALITYBIO-B in tandem. Additionally, the company's core pipeline B7-H3 ADC (Elfe-D) recently received NMPA Breakthrough Therapy Designation, while its A-share IPO application has been accepted by the Shanghai Stock Exchange and entered the inquiry stage. Multiple brokerages have issued Buy ratings, with Dongwu Securities initiating coverage and projecting revenue of RMB 2.05 billion to RMB 2.60 billion for the period ahead. These fundamental catalysts continue to accumulate, supporting ongoing valuation recovery.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜DUALITYBIO-B Rises 5.09% in Regular Trading, Biotech Sector Strength Drives Rebound Continuation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜DUALITYBIO-B Rises 5.09% in Regular Trading, Biotech Sector Strength Drives Rebound Continuation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-07 14:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, DUALITYBIO-B rose 5.09% in regular trading, trading at 191.6 HKD/share, with turnover of approximately HKD 149 million. The stock had previously plunged 13.7% on July 30 due to GSK competitive pressure and has been gradually stabilizing in recent sessions.</p><p>On the news front, the Hong Kong-listed biotech sector rallied broadly, with Remegen up 8.99%, Transthera-B up 7.11%, BeOne Medicines up 4.86%, Akeso up 3.96%, and Innovent Bio up 2.86%, reflecting a significant recovery in sector sentiment that lifted DUALITYBIO-B in tandem. Additionally, the company's core pipeline B7-H3 ADC (Elfe-D) recently received NMPA Breakthrough Therapy Designation, while its A-share IPO application has been accepted by the Shanghai Stock Exchange and entered the inquiry stage. Multiple brokerages have issued Buy ratings, with Dongwu Securities initiating coverage and projecting revenue of RMB 2.05 billion to RMB 2.60 billion for the period ahead. These fundamental catalysts continue to accumulate, supporting ongoing valuation recovery.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1179387639","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179387639","pubTimestamp":1786083511,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, DUALITYBIO-B rose 5.09% in regular trading, trading at 191.6 HKD/share, with turnover of approximately HKD 149 million. The stock had previously plunged 13.7% on July 30 due to GSK...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"走势提醒|DUALITYBIO-B 常规交易上涨 5.09%，生物技术板块走强推动反弹持续","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"On August 7, DUALITYBIO-B rose 5.09% in regular trading, trading at 191.6 HKD/share, with turnover of approximately HKD 149 million. The stock had previously plunged 13.7% on July 30 due to GSK competitive pressure and has been gradually stabilizing in recent sessions.On the news front, the Hong Kong-listed biotech sector rallied broadly, with Remegen up 8.99%, Transthera-B up 7.11%, BeOne Medicines up 4.86%, Akeso up 3.96%, and Innovent Bio up 2.86%, reflecting a significant recovery in sector sentiment that lifted DUALITYBIO-B in tandem. Additionally, the company's core pipeline B7-H3 ADC (Elfe-D) recently received NMPA Breakthrough Therapy Designation, while its A-share IPO application has been accepted by the Shanghai Stock Exchange and entered the inquiry stage. Multiple brokerages have issued Buy ratings, with Dongwu Securities initiating coverage and projecting revenue of RMB 2.05 billion to RMB 2.60 billion for the period ahead. These fundamental catalysts continue to accumulate, supporting ongoing valuation recovery.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179387639","isCrawlerRequest":true}